Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial-Reference-Cited by-同舟云学术

Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial

Published:2021-07-28 Issue:1 Volume:19 Page:120-128
ISSN:1612-9059
Container-title:Esophagus
language:en
Short-container-title:Esophagus

Author:

Wang Zhiqiang,Hu Mingtao,Hu Yihuai,Li Qiaoqiao,Wu Jiadi,Fong William Pat,Ren Chao,Wang Deshen,Tan Qiong,Yang Hong,Li Yuhong^ORCID

Funder

Science and Technology Project of Guangdong Esophageal Cancer Research Institute

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

https://link.springer.com/content/pdf/10.1007/s10388-021-00864-8.pdf

Reference26 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

2. Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360–73.

3. Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.

4. Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally advanced esophageal carcinoma: ASCO Guideline. J Clin Oncol. 2020. https://doi.org/10.1200/JCO.20.00866.

5. Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v50–7.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conversion chemoradiotherapy combined with nab-paclitaxel plus cisplatin in patients with locally advanced borderline-resectable or unresectable esophageal squamous cell carcinoma: a phase i/ii prospective cohort study;Strahlentherapie und Onkologie;2024-08-12

2. Preoperative camrelizumab combined with chemotherapy for borderline resectable ESCC: A single-arm, prospective, phase 2 study;Med;2024-08

3. Conversion Chemoradiotherapy Combined with nab-paclitaxel plus Cisplatin in Patients with Locally Advanced Borderline-Resectable or Unresectable Esophageal Squamous Cell Carcinoma: a Phase Ⅰ/Ⅱ Prospective Cohort Study;2024-02-26

4. Study on the predictive value of pretreatment peripheral blood inflammatory markers regarding immunotherapy in patients with inoperable advanced or locally advanced oesophageal squamous cell carcinoma;Scandinavian Journal of Gastroenterology;2024-02-16

5. Preoperative Camrelizumab Combined with Chemotherapy for Borderline Resectable Esophageal Squamous Cell Carcinoma (BRES-1): A Single-Arm, Prospective, Phase 2 Study;2024